NY-ALVAREZ-&-MARSAL
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”
Henry Chambers, Hong Kong
Eden Chen, Shanghai
Sally Sun, Hong Kong
Pedro Bortolotto, São Paulo
Marcelo Compte, São Paulo
Rodrigo Domingues, São Paulo
Lilian Giorgi, São Paulo
Rodrigo Hong, São Paulo
Henrique Kanashiro, São Paulo
Rafael Mendonca Rodrigues, São Paulo
Fabio Missiato, São Paulo
Corporate Performance Improvement
Tiffany Guthrie, Houston
Mike Hall, San Francisco
John McKinnis, Dallas
Sam Rudkin, Atlanta
Kenneth Cochran, Charlotte
Jeffrey Dwyer, Chicago
Lakshman Lakshmanan, Dallas
Chad Lusk, Chicago
Joanna Rangarajan, New York
Global Disputes and Investigations
Lee Betteridge, London
Gary Foster, London
EMEA – Performance Improvement
Private Equity Performance Improvement
Nicola Barbini, London
Chris Gobby, London
Britta Mittler, Frankfurt
Till Prinz, Dusseldorf
Tim Veen, Munich
Gerardo Villalba Bello, Madrid
Ysabel Gaspar Zayco, London
Robert Bradbury, London
Dominic Roope, London
Jatin Arora, Dubai
Mark Bennett, Paris
Daran Hopper, London
Dirk Naujokat, Munich
Steve Trainor, London
Diana Wong, London
EMEA Restructuring
Barry Lynch, Grand Cayman
Helen Skeates, London
David Johnston, London
José Miguel Gómez Rivas, Madrid
Bill Ozturk, Dubai
Environmental, Social and Governance (ESG)
Stephanie Weiler, Chicago
JoyAnn Book, Phoenix
Bianca A. Briola Charlotte
David Nidetz, Detroit
Rich Rieger, Chicago
Anup Gandhi, Mumbai
Pranav Sheth, Mumbai
Infrastructure & Capital Projects
Sue Frost, Washington, D.C.
Alan Richard, Washington, D.C.
Private Equity Performance Group
Kent Edgerton, Nashville
Jana Gold, Washington, D.C.
Brad Howard, New York
Larry Thomas, Tampa
Klaus Weisenberger, San Francisco
Daniel Harlan, Washington, D.C
Restructuring & Turnaround (North America)
Taylor Atwood, Dallas
Matthew Davidson, Detroit
Chad Ellison, Calgary
Kamila Khairoullina, New York
Mark Sidorenkov, Phoenix
Jeff Sielinski, Detroit
Michael Zembillas, Atlanta
Simon Bernstein, New York
Stephanie Doughty, Houston
Michael Farkas, New York
Simon Gore, London
Jack Hollyman, London
Jac Emilio Martinez, Miami
Joseph Plati, New York
Brendan Sinnott, New York
Katya Umanskaya, Los Angeles
Global Transaction Advisory Group
Anuj Astir, New York
Nout Brugman, Amsterdam
David Cho, Chicago
Vitor Garcia, Sao Paulo
Jimmy Glenn, Atlanta
Nick Lynch, London
Jai Tandan, Mumbai
Rhett Taylor, Nashville
Nick Thoele, New York
Cedric Zana, Paris
Cole Corbin, New York
Steven Fischoff, Chicago
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom